Bulk Suggestion
Bulk ID:
sabicool/12.11.24-06:47AM
Accepted at: Feb, 23, 2025
4:08 a.m.
Author:
sabicool
Co-authors:
Stapedius
Related Deck:
1675118865074
Accepted
Rationale for new note
various cards on various topics
Text
How is decompensation prevented in compensated cirrhosis with clinically significant portal hypertension?
{{c1::Treat the underlying cause of chronic liver disease (e.g. alcohol abstinence)}}
{{c1::β-blocker (preferably carvedilol)}}
{{c1::Treat the underlying cause of chronic liver disease (e.g. alcohol abstinence)}}
{{c1::β-blocker (preferably carvedilol)}}
Extra
Variceal surveillance required in those who cannot tolerate β-blockers
The nonselective beta blockers, carvedilol and propranolol, are both effective in lowering portal pressure. However, carvedilol has additional vasodilator activity (as it blocks both alpha and beta receptors), producing a greater reduction in portal pressure compared with propranolol, and less systemic hypotension for an equivalent effect on portal pressure
In the absence of clinically significant portal hypertension, beta blockers have no proven benefit in cirrhosis.
The nonselective beta blockers, carvedilol and propranolol, are both effective in lowering portal pressure. However, carvedilol has additional vasodilator activity (as it blocks both alpha and beta receptors), producing a greater reduction in portal pressure compared with propranolol, and less systemic hypotension for an equivalent effect on portal pressure
In the absence of clinically significant portal hypertension, beta blockers have no proven benefit in cirrhosis.
Titrate the dose against clinical tolerance; maintain resting heart rate above 60 beats per minute and systolic blood pressure above 90 mmHg. Patients taking beta blockers to prevent decompensation do not require endoscopic surveillance as it will not change management.
Personal Notes
Empty field
Missed Questions
Empty field
Oxford Handbook
Empty field
First Aid
Empty field
AMBOSS
Empty field
eTG Complete

Talley & O'Connor
Empty field
Additional Resources
Empty field
Source
eTG - Prevention of decompensation in patients with compensated cirrhosis https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Liver Disorders&topicfile=c_LDG_Prevention-of-decompensation-in-patients-with-compensated-cirrhosis_topic_1&guidelinename=auto§ionId=c_LDG_Prevention-of-decompensation-in-patients-with-compensated-cirrhosis_topic_1#c_LDG_Prevention-of-decompensation-in-patients-with-compensated-cirrhosis_topic_1 Published June 2023, Accessed 10 October 2024
One by one
y
Tags
#Malleus_CM::#eTG_Complete::Liver_Disorders::Cirrhosis_and_its_complications::Prevention_of_decompensation_in_patients_with_compensated_cirrhosis
#Malleus_CM::#Question_Banks::eMedici::0-999::56
#Malleus_CM::#Question_Banks::eMedici::0-999::624
#Malleus_CM::#Question_Banks::eMedici::1000-1999::1344
#Malleus_CM::#Resources_by_Rotation::Internal_Medicine::Gastroenterology
#Malleus_CM::#Resources_by_Rotation::Surgery::Upper_GI_&_HPB
#Malleus_CM::#Subjects::Gastroenterology::10_Liver::02_Chronic_Liver_Disease::Cirrhosis::12_Screening/Prevention